DDInter484 DDInter1763
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dasatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Dasatinib {u} (Compound) upregulates {v} (Gene) TF
TF {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Dasatinib {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Dasatinib {u} (Compound) binds {v} (Gene) TESK1
TESK1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Dasatinib {u} (Compound) downregulates {v} (Gene) TFDP1
TFDP1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Dasatinib {u} (Compound) upregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Dasatinib {u} (Compound) binds {v} (Gene) CSK
CSK {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Dasatinib {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Febrile neutropenia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Dasatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Dasatinib (Compound) upregulates TF (Gene) and TF (Gene) is upregulated by Temsirolimus (Compound)
Dasatinib (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Temsirolimus (Compound)
Dasatinib (Compound) binds TESK1 (Gene) and TESK1 (Gene) is upregulated by Temsirolimus (Compound)
Dasatinib (Compound) downregulates TFDP1 (Gene) and TFDP1 (Gene) is downregulated by Temsirolimus (Compound)
Dasatinib (Compound) upregulates LRPAP1 (Gene) and LRPAP1 (Gene) is downregulated by Temsirolimus (Compound)
Dasatinib (Compound) binds CSK (Gene) and CSK (Gene) is downregulated by Temsirolimus (Compound)
Dasatinib (Compound) causes Febrile neutropenia (Side Effect) and Febrile neutropenia (Side Effect) is caused by Temsirolimus (Compound)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)